Table 4.
Clinical characteristics of the eight women who progressed to high-grade squamous in Table 2. Or cervical carcinoma (HSIL/CIN2+) during follow-up.
| Case | Results at First Visit | Results at Progression | ||||
|---|---|---|---|---|---|---|
| Cytology | Biopsy | HPV E7 mRNA | Cytology | Biopsy | Time to Progression * | |
| 1 | HSIL | Negative | Positive | Negative | HSIL/CIN3 | 22.8 |
| 2 | HSIL | Negative | Positive | Negative | HSIL/CIN3 | 15.1 |
| 3 | HSIL | CIN1 | Positive | HSIL | HSIL/CIN2 | 14.3 |
| 4 | HSIL | Negative | Positive | LSIL | HSIL/CIN3 | 12.8 |
| 5 | LSIL | Negative | Positive | HSIL | HSIL/CIN2 | 12.4 |
| 6 | LSIL | Negative | Negative | HSIL | HSIL/CIN2 | 12.3 |
| 7 | LSIL | CIN 1 | Positive | HSIL | HSIL/CIN2 | 18.8 |
| 8 | LSIL | Negative | Positive | HSIL | HSIL/CIN3 | 67.6 |
HPV: Human papillomavirus; mRNA: messenger RNA; LSIL: Low-grade intraepithelial lesion; CIN: Cervical intraepithelial neoplasia. * Time to progression is expressed in months.